Increased procoagulant activity of red blood cells in the presence of cisplatin
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 18
- DOI:
- No doi available
- Key Word:
- procoagulant activity;red blood cell;phosphatidylserine;cisplatin;lactadherin
Abstract： Background Cisplatin based chemotherapy is a well recognized risk factor for coagulation disordrs and thrombosis.The pathophysiological mechanisms by which cisplatin promote thrombosis are not well understood.Methods Red blood cells (RBCs) were separated from peripheral blood of patients with breast cancer (n=10) and healthy adults (n=6) and treated with cisplatin. Coagulation time of RBCs was assessed by one step recalcification time and the productions of thrombin, intrinsic and extrinsic factor Xa were measured in the presence or absence of various concentrations of lactadherin. Exposed phosphatidylserine was stained with lactadherin and observed by confocal microscopy and flow cytometry.Results Neither fresh RBCs nor RBCs treated without cisplatin had potent procoagulant activity. Cisplatin treatment increased procoagulant activity of RBCs in a cell number- and concentration-dependent manner. Exposed phosphatidylserine was stained with lactadherin and after cisplatin treatment, strong fluorescence was revealed by confocal microscopy. Lactadherin bound RBCs from patients with breast cancer increased from (1.9±0.5)% on control RBCs to (68.0±3.5)% on RBCs treated with 10 pmol/L cisplatin for 24 hours.Conclusions Cisplatin treatment increases procoagulant activity of RBCs, which have a strong association with exposure of phosphatidylserine. The increased procoagulant activity may contribute to the pathogenesis of thrombophilia during cisplatin based chemotherapy in breast cancer patients.
- [1]A S, Gallus.Prevention of post-operative deep leg vein thrombosis in patients with cancer.[J].1997,78.
- [2]M B, Donati,A, Falanga.Pathogenetic mechanisms of thrombosis in malignancy.[J].2001,106(1-2).
- [3]Herrington JD,Wong L,Cool RM.Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide.[J].2002,22(9).
- [4]J D, Stubbs,C, Lekutis,K L, Singer,etc.cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences.[J].1990,87.
- [5]J W, Govers-Riemslag,M P, Janssen,R F, Zwaal,etc.Prothrombin activation on dioleoylphosphatidylcholine membranes.[J].1994,220(1).
- [6]Lauber K,Wesselborg S,Schulze-Osthoff K,etc.Human mature red blood cells express caspase-3 and caspase-8, but are devoid of mitochondrial regulators of apoptosis.[J].2001,8(12).
- [7]Levine MN.Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.[J].1997,78(1).
- [8]Morrissey JH.Tissue factor: an enzyme cofactor and a true receptor.[J].2001,86(1).
- [9]Jon C, Anders,Perry W, Grigsby,Anurag K, Singh.Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature.[J].2006,1.
- [10]Fisher, B.,Costantino, J..A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative...[J].1989,320(8).
- [11]G, Luzzatto,A I, Schafer.The prethrombotic state in cancer.[J].1990,17.
- [12]L S, Brunauer,M S, Moxness,W H, Huestis.Hydrogen peroxide oxidation induces the transfer of phospholipids from the membrane into the cytosol of human erythrocytes.[J].1994,33(15).
- [13]Boas FE,Forman L,Beutler E.Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia.[J].1998,95(6).
- [14]D, Helley,A, Eldor,R, Girot,etc.Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia.[J].1996,76.
- [15]Caprino L,Togna AR,Franconi M,etc.Cisplatin triggers platelet activation.[J].2000,99(5).
- [16]Jane Hvarregaard,Mikkel H. Andersen,Lars Berglund,etc.Characterization of Glycoprotein PAS-6/7 from Membranes of Bovine Milk Fat Globules[J].1996,240(3).
- [17]Arena AA,Gilbert GE.Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine.[J].1996,271(19).
- [18]Lee AY,Levine MN.The thrombophilic state induced by therapeutic agents in the cancer patient.[J].1999,25(2).
- [19]Chao-Hung Ho.The hemostatic effect of adequate red cell transfusion in patients with anemia and thrombocytopenia[J].1996,36(3).
- [20]Graham J, Caine,Paul S, Stonelake,Gregory Y H, Lip,etc.The hypercoagulable state of malignancy: pathogenesis and current debate.[J].1900,4(6).
- [21]Lip GY,Chin BS,Blann AD.Cancer and the prothrombotic state.[J].2002,3(1).
- [22]S E, Feffer,L S, Carmosino,R L, Fox.Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil.[J].1989,63(7).
- [23]Freytes CO.Thromboembolic complications related to central venous access catheters in cancer patients.[J].2007,33(4).
- [24]J T, Licciardello,J L, Moake,C K, Rudy,etc.Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy.[J].1985,42.
- [25]Shin JH,Lim KM,Noh JY,etc.Lead-induced procoagulant activation of erythrocytes through phosphatidylserine exposure may lead to thrombotic diseases.[J].2007,20(1).
- [26]Le Gac S,Vermes I,van den Berg A.Quantum dots based probes conjugated to annexin V for photostable apoptosis detection and imaging[J].2006,6(9).
- [27]John Walsh,Helen R. Wheeler,Carolyn L. Geczy.Modulation of tissue factor on human monocytes by cisplatin and adriamycin[J].1992,81(4).
- [28]M N, Levine,M, Gent,J, Hirsh,etc.The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.[J].1988,318.